- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe rheumatoid arthritis
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 798KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 43KB)
Upadacitinib – November 2020
Upadacitinib: Tablet 15 mg; Rinvoq®
Last updated
19 March 2021